LogicBio Therapeutics, Inc. (LOGC)
$2.07
Rating:
Recommendation:
-
| Symbol | LOGC |
|---|---|
| Price | $2.07 |
| Beta | 4.618 |
| Volume Avg. | 0.57M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 0.2573-3.4 |
| 1y Target Est | - |
| DCF Unlevered | LOGC DCF -> | |
|---|---|---|
| DCF Levered | LOGC LDCF -> | |
| ROE | -88.35% | Strong Sell |
| ROA | -46.82% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 63.40% | Buy |
| P/E | -1.85 | Sell |
| P/B | 4.34 | Strong Buy |
Latest LOGC news
About
Download (Excel)LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..